142 related articles for article (PubMed ID: 24124898)
1. Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
Xu S; Xu T; Zhang L; Zhang Z; Luo J; Liu Y; Lu X; Tu Z; Ren X; Ding K
J Med Chem; 2013 Nov; 56(21):8803-13. PubMed ID: 24124898
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Chang S; Zhang L; Xu S; Luo J; Lu X; Zhang Z; Xu T; Liu Y; Tu Z; Xu Y; Ren X; Geng M; Ding J; Pei D; Ding K
J Med Chem; 2012 Mar; 55(6):2711-23. PubMed ID: 22339342
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
Wu CH; Coumar MS; Chu CY; Lin WH; Chen YR; Chen CT; Shiao HY; Rafi S; Wang SY; Hsu H; Chen CH; Chang CY; Chang TY; Lien TW; Fang MY; Yeh KC; Chen CP; Yeh TK; Hsieh SH; Hsu JT; Liao CC; Chao YS; Hsieh HP
J Med Chem; 2010 Oct; 53(20):7316-26. PubMed ID: 20961149
[TBL] [Abstract][Full Text] [Related]
5. A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR
Yu L; Huang M; Xu T; Tong L; Yan XE; Zhang Z; Xu Y; Yun C; Xie H; Ding K; Lu X
Eur J Med Chem; 2017 Jan; 126():1107-1117. PubMed ID: 28033579
[TBL] [Abstract][Full Text] [Related]
6. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Gendreau SB; Ventura R; Keast P; Laird AD; Yakes FM; Zhang W; Bentzien F; Cancilla B; Lutman J; Chu F; Jackman L; Shi Y; Yu P; Wang J; Aftab DT; Jaeger CT; Meyer SM; De Costa A; Engell K; Chen J; Martini JF; Joly AH
Clin Cancer Res; 2007 Jun; 13(12):3713-23. PubMed ID: 17575237
[TBL] [Abstract][Full Text] [Related]
8. Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
Han C; Huang Z; Zheng C; Wan L; Zhang L; Peng S; Ding K; Ji H; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4738-48. PubMed ID: 23668441
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
Han C; Wan L; Ji H; Ding K; Huang Z; Lai Y; Peng S; Zhang Y
Eur J Med Chem; 2014 Apr; 77():75-83. PubMed ID: 24607591
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Zhou W; Liu X; Tu Z; Zhang L; Ku X; Bai F; Zhao Z; Xu Y; Ding K; Li H
J Med Chem; 2013 Oct; 56(20):7821-37. PubMed ID: 24053674
[TBL] [Abstract][Full Text] [Related]
11. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
Han C; Huang Z; Zheng C; Wan L; Lai Y; Peng S; Ding K; Ji H; Zhang Y
Eur J Med Chem; 2013 Aug; 66():82-90. PubMed ID: 23792318
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
[TBL] [Abstract][Full Text] [Related]
16. 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).
Chan S; Han K; Qu R; Tong L; Li Y; Zhang Z; Cheng H; Lu X; Patterson A; Smaill J; Ren X; Ding J; Xie H; Ding K
Bioorg Med Chem Lett; 2015 Oct; 25(19):4277-81. PubMed ID: 26259806
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.
Zhang H; Wang J; Zhao HY; Yang XY; Lei H; Xin M; Cao YX; Zhang SQ
Bioorg Med Chem; 2018 Jul; 26(12):3619-3633. PubMed ID: 29853340
[TBL] [Abstract][Full Text] [Related]
18. Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.
Shiao HY; Coumar MS; Chang CW; Ke YY; Chi YH; Chu CY; Sun HY; Chen CH; Lin WH; Fung KS; Kuo PC; Huang CT; Chang KY; Lu CT; Hsu JT; Chen CT; Jiaang WT; Chao YS; Hsieh HP
J Med Chem; 2013 Jul; 56(13):5247-60. PubMed ID: 23808327
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Cha MY; Lee KO; Kang SJ; Jung YH; Song JY; Choi KJ; Byun JY; Lee HJ; Lee GS; Park SB; Kim MS
J Med Chem; 2012 Mar; 55(6):2846-57. PubMed ID: 22372864
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
